{
    "patient": {
        "Name": "Terry Simmons",
        "DateOfBirth": "1966-10-29",
        "Sex": "Male",
        "Diagnosis": "Chronic lymphocytic leukemia (CLL)",
        "BodyPart": "Leukemia",
        "Physician": "Dr. James Miller",
        "TreatingInstitution": "Austin Inc"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Leukemia",
            "CollectedDate": "2023-11-11",
            "ReceivedDate": "2023-11-18",
            "TumorPercentage": "1%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-11-13",
            "ReceivedDate": "2023-11-14"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "PKLR",
                "DNA Alteration": "c.1436G>A",
                "GeneMutation": "p.R479H Spliceregionvariant-GOF",
                "VariantAlleleFraction": "14.93%"
            },
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Nonsense-LOF",
                "VariantAlleleFraction": "29.57%"
            },
            {
                "Gene": "SDHB",
                "DNA Alteration": "c.487T>C",
                "GeneMutation": "p.S163P Frameshift-GOF",
                "VariantAlleleFraction": "27.84%"
            },
            {
                "Gene": "CD74",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.P98S Nonsense-LOF",
                "VariantAlleleFraction": "2.72%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "PAX5",
                "DNA Alteration": "c.964G>A",
                "GeneMutation": "p.G183S Spliceregionvariant-LOF",
                "VariantAlleleFraction": "17.08%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": []
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "21 m/Mb",
            "Tmbpercentile": "48%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "EGFR",
                "DNA Alteration": "c.2310_2311ins9",
                "GeneMutation": "p.L792Y Frameshift-LOF",
                "VariantAlleleFraction": "13.59%"
            },
            {
                "Gene": "NTRK1",
                "DNA Alteration": "c.1792C>T",
                "GeneMutation": "p.G607V Spliceregionvariant-LOF",
                "VariantAlleleFraction": "3.11%"
            },
            {
                "Gene": "HDAC2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.E455fs*7 Nonsense-GOF",
                "VariantAlleleFraction": "3.47%"
            },
            {
                "Gene": "SDHD",
                "DNA Alteration": "c.34G>A",
                "GeneMutation": "p.G12S Frameshift-LOF",
                "VariantAlleleFraction": "6.79%"
            },
            {
                "Gene": "HSP90B1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.I66T Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "2.95%"
            },
            {
                "Gene": "ALDH2",
                "DNA Alteration": "c.1510G>A",
                "GeneMutation": "p.E504K Frameshift-LOF",
                "VariantAlleleFraction": "4.9%"
            },
            {
                "Gene": "SDHD",
                "DNA Alteration": "c.34G>A",
                "GeneMutation": "p.G12S Nonsense-GOF",
                "VariantAlleleFraction": "3.93%"
            },
            {
                "Gene": "FGFR4",
                "DNA Alteration": "c.1162G>A",
                "GeneMutation": "p.G388R Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "7.38%"
            },
            {
                "Gene": "SDHD",
                "DNA Alteration": "c.34G>A",
                "GeneMutation": "p.G12S Spliceregionvariant-GOF",
                "VariantAlleleFraction": "9.19%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "SRSF2",
        "SDHD",
        "ZEB2"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "PKLR",
                "DNA Alteration": "c.1436G>A",
                "GeneMutation": "p.R479H Spliceregionvariant-GOF",
                "description": "STK11 (LKB1) encodes an enzyme in the serine/threonine kinase family that is responsible for maintaining energy metabolism and cellular polarization through the activation of AMP-activated protein kinase and other members of the AMPK family. The enzyme also acts as a tumor suppressor by regulating cell growth. Loss of function mutations, copy number loss, epigenetic variation, and underexpression of STK11 are associated with cancer progression.",
                "VariantAlleleFraction": "14.93%"
            },
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Nonsense-LOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "29.57%"
            },
            {
                "Gene": "SDHB",
                "DNA Alteration": "c.487T>C",
                "GeneMutation": "p.S163P Frameshift-GOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "27.84%"
            },
            {
                "Gene": "CD74",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.P98S Nonsense-LOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "2.72%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "PAX5",
                "DNA Alteration": "c.964G>A",
                "GeneMutation": "p.G183S Spliceregionvariant-LOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "17.08%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-11-10"
    },
    "other": {
        "ReportId": "8954",
        "ReportDate": "2023-11-15",
        "SignedBy": "James Miller",
        "Supervisor": "Dr. Melissa Powers"
    }
}